T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin

• Published in: Acta pharmacologica Sinica Vol. 45; no. 10; pp. 2186 - 2198
• Main Authors: Liu, Jun-jun, Pan, Zhi-di, Yue, Ya-li, Wang, Shu-sheng, Chen, Jie, Jiang, Hua, Zhang, Bao-hong, Wu, Ming-yuan, Yuan, Yun-sheng, Bian, Yan-lin, Yin, Hai-yang, Wang, Lei, Li, Jun-yan, Gilly, John, Xie, Yue-qing, Zhu, Jian-wei
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.10.2024
• Subjects: Biomedical and Life Sciences; Biomedicine; Immunology; Internal Medicine; Medical Microbiology; Pharmacology/Toxicology; Vaccine; paclitaxel; T cell engaging bispecific antibodies; MSLN490; solid tumors; mesothelin
• ISSN: 1671-4083; 1745-7254; 1745-7254
• DOI: 10.1038/s41401-024-01316-6

T cell engaging bispecific antibodies (TCBs) have recently become significant in cancer treatment. In this study we developed MSLN490, a novel TCB designed to target mesothelin (MSLN), a glycosylphosphatidylinositol (GPI)-linked glycoprotein highly expressed in various cancers, and evaluated its efficacy against solid tumors. CDR walking and phage display techniques were used to improve affinity of the parental antibody M912, resulting in a pool of antibodies with different affinities to MSLN. From this pool, various bispecific antibodies (BsAbs) were assembled. Notably, MSLN490 with its IgG-[L]-scFv structure displayed remarkable anti-tumor activity against MSLN-expressing tumors (EC 50 : 0.16 pM in HT-29-hMSLN cells). Furthermore, MSLN490 remained effective even in the presence of non-membrane-anchored MSLN (soluble MSLN). Moreover, the anti-tumor activity of MSLN490 was enhanced when combined with either Atezolizumab or TAA × CD28 BsAbs. Notably, a synergistic effect was observed between MSLN490 and paclitaxel, as paclitaxel disrupted the immunosuppressive microenvironment within solid tumors, enhancing immune cells infiltration and improved anti-tumor efficacy. Overall, MSLN490 exhibits robust anti-tumor activity, resilience to soluble MSLN interference, and enhanced anti-tumor effects when combined with other therapies, offering a promising future for the treatment of a variety of solid tumors. This study provides a strong foundation for further exploration of MSLN490’s clinical potential.